Adagrasib
- Generic Name
- Adagrasib
- Brand Names
- Krazati
- Drug Type
- Small Molecule
- Chemical Formula
- C32H35ClFN7O2
- CAS Number
- 2326521-71-3
- Unique Ingredient Identifier
- 8EOO6HQF8Y
- Background
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), ...
- Indication
Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06497556
- Locations
- 🇺🇸
Banner Health MD Anderson AZ, Gilbert, Arizona, United States
🇺🇸Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT06412198
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ryan Gentzler, MD
- Target Recruit Count
- 30
- Registration Number
- NCT06248606
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination with the PARP Inhibitor Olaparib in Patients with KRAS G12C Mutated Advanced Solid Tumors, with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06130254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT06039384
- Locations
- 🇮🇹
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo, Italy
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Banner Md Anderson Cancer Center, Greeley, Colorado, United States
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06026410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT06024174
- Locations
- 🇺🇸
Local Institution - 0025, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0047, Los Angeles, California, United States
🇦🇺Local Institution - 0053, Westmead, New South Wales, Australia
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05924152
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical Research Unit Daytona Beach), Daytona Beach, Florida, United States
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05853575
- Locations
- ðŸ‡ðŸ‡·
Local Institution - 525, Pula, Croatia
🇺🇸Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸Local Institution - 106, Chicago, Illinois, United States
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05848843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.